Thus, a change in serum androgen level or direct modulation of the PSA gene by some therapeutic agents used in the treatment of prostate cancer might contribute to a false decrease in PSA concentration, not associated with the cytoreduction [18]. Here, KLK3 is linked to prostate cancer.